Published data suggest that denosumab is highly effective in rapidly halting osteoclastic activity and expansion of focal lesions in RANKL-mediated bone tumors (Figs. 1 and 2) and FD (Fig. 3), with subsequent ossification during continued treatment (2, 10, 19, 27, 32, 38, 41-66). The gene discussed is TNFSF11; the disease is bone neoplasm.